

***Company Location***

PMB 382  
10105 E. Via Linda, Suite 103  
Scottsdale, AZ 85258

***Contact Numbers***

Tel: (480) 614-2874  
Fax: (480) 614-0560

***Contact***

Steven I. Kern  
**Title:** Press Contact  
[stevenikern@mdch.net](mailto:stevenikern@mdch.net)

**Overview**

Meditech Pharmaceutical, Inc. has a 19-year history of developing successful anti-infective drugs for human, veterinary and agricultural applications. Anti-infective drugs are agents that inhibit or prevent infections. The firm has completed various stages of planning and development of products containing our proprietary drugs Viraplex® and MTCH-24™. Both drugs have already demonstrated the potential for use in the treatment of diseases caused by viruses. MTCH-24™ has demonstrated positive preliminary test results against acne, citrus canker, herpes, and other viral and fungal problems. Citrus canker is a plant disease that causes loss of oranges, other citrus fruit trees, and some vegetables. Viraplex® has been tested against orofacial and genital herpes. Orofacial herpes affects the area around the mouth and face. In addition, the drug has demonstrated positive results in the area of human tumor cell reduction.

**Research & Development**

Since 1982, Meditech has researched and tested several drugs, combinations of drugs and antimicrobial agents in their efforts to develop successful anti-infective drugs for human, veterinary and agricultural applications. Among other accomplishments, the firm's efforts have resulted in the development of its proprietary MTCH-24™, MDCH and Viraplex® drugs. MTCH-24™ has been proven to be effective in vitro against a range of Herpes viruses. Subsequent tests by the firm have also proven the drug's effectiveness

**Clinical Trials**

Meditech's products have been successfully tested in a number of clinical tests conducted by major universities, governmental entities and institutions worldwide. Some of these include:

**Human Tumor Studies by the National Cancer Institute**

Launched in 1987, this high-profile series of studies initially screened more than 60,000 drugs to determine their effectiveness against cancer-related tumors, of which 1,700 prospects were selected for a series of in-vivo tests in 1994. Of these, less than 10 - including Meditech's proprietary drug, Viraplex®, were proven successful in the treatment and reduction of human tumor cells from breast and ovarian cancer patients. In fact, Viraplex® was proven useful in reducing the size of human tumor cells by as much as 100% as of the reports last findings, which were released in May, 1995.

*Note: These studies have been suspended pending the development of a more soluble form of the drug.*

*However, recent developments in testing at the School of Pharmacy in London, England, lead us to believe that the solubility problem has been solved.*

**Phase III Clinical Trials For Genital and Oral Herpes**

Viraplex® has already completed more than 50% of an FDA-authorized 320 patient Phase III clinical trials for safety and effectiveness in humans. The trials will involve testing on 160 patients with genital herpes and 160 patients with orofacial herpes.

*Note: these trials have been suspended pending the firm's re-financing.*